Presentation to highlight preclinical data from the company’s lead cell therapy, ERNA-101, demonstrating potential to reprogram the ovarian tumor microenvironment and advance toward clinical trials
Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research
Seeking Alpha / 2 hours from now 1 Views
Presentation to highlight preclinical data from the company’s lead cell therapy, ERNA-101, demonstrating potential to reprogram the ovarian tumor microenvironment and advance toward clinical trials
Comments